Stay updated on Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Revision: v3.3.4 has been added and Revision: v3.3.3 has been removed from the Study Documents section. This is a minor metadata update that does not affect study content, results, or how users interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:11:41.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The page now lists a specific Location (Charlotte, North Carolina) under Locations. The old North Carolina Locations entry and the HHS Vulnerability Disclosure link were removed, and the page revision updated from v3.3.2 to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T08:50:10.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    Footer revision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T17:31:14.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Publications section wording updated to indicate publications are about the study results, and a new Revision: v3.3.1 tag appears replacing the older v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T14:34:03.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Removed a generic NIH operating-status notice; the study details, eligibility criteria, outcomes, and navigation remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T06:54:23.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    No notable content or layout changes were observed between the two screenshots. The page still displays the same study details, sections, and links as before.
    Difference
    0.4%
    Check dated 2025-11-03T01:17:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial page.